期刊文献+

肠道菌群与非酒精性脂肪性肝病研究进展 被引量:5

Research progress of the correlation between intestinal microbiota and nonalcoholic fatty liver disease
下载PDF
导出
摘要 非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)发病率不断升高,对其发生、发展及防治研究变得极为迫切。近年来肠道菌群被认为是机体一个重要的"特殊器官",参与机体代谢及相关疾病的发生、发展,与NAFLD关系密切。本文就肠道菌群与NAFLD的关系研究进行综述。 Currently, the morbidity of nonalcoholic fatty liver disease (NAFLD) is increasing, so it is extremely pivotal to study the development, progression, prevention and treatment of NAFLD. Intestinal microbiota, as an important and special organ of the body, intimately participates in the metabolism of the body, and the development and progression of NAFLD as well. In this article, the correlation between intestinal microbiota and NAFLD is reviewed.
作者 周达 范建高
出处 《传染病信息》 2015年第4期200-202,206,共4页 Infectious Disease Information
基金 国家重点基础研究发展计划(973计划)项目(2012CB517501) 国家自然基金(81070322 81270491 81470840) 上海市科委课题(0914090350 10411956300) 中国肝炎防治基金(XJS20120501) 上海市卫生局百人计划(XBR2011007)
关键词 脂肪肝 肠杆菌科 生态失调 内毒素类 乙醇 fatty liver Enterobacteriaceae dysbiosis endotoxins ethanol
  • 相关文献

二级参考文献59

  • 1Nissen S.E.,Wolski K.,刘少伟.罗格列酮对心肌梗死风险和心血管性死亡风险的影响[J].世界核心医学期刊文摘(心脏病学分册),2007(10):15-16. 被引量:22
  • 2Jia Xiao,Rui Guo,Man Lung Fung,Emily C Liong,George L Tipoe.Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges[J].Hepatobiliary & Pancreatic Diseases International,2013,12(2):125-135. 被引量:14
  • 3M. Cnop,P. J. Havel,K. M. Utzschneider,D. B. Carr,M. K. Sinha,E. J. Boyko,B. M. Retzlaff,R. H. Knopp,J. D. Brunzell,S. E. Kahn MB ChB.Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex[J]. Diabetologia . 2003 (4)
  • 4Ronit Shiri-Sverdlov,Kristiaan Wouters,Patrick J. van Gorp,Marion J. Gijbels,Benoit Noel,Laurent Buffat,Bart Staels,Nobuyo Maeda,Marc van Bilsen,Marten H. Hofker.Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates[J]. Journal of Hepatology . 2005 (4)
  • 5Guruprasad P. Aithal,James A. Thomas,Philip V. Kaye,Adam Lawson,Stephen D. Ryder,Ian Spendlove,Andrew S. Austin,Jan G. Freeman,Linda Morgan,Jonathan Webber.Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis[J]. Gastroenterology . 2008 (4)
  • 6Yu Li,Shanqin Xu,Maria M. Mihaylova,Bin Zheng,Xiuyun Hou,Bingbing Jiang,Ogyi Park,Zhijun Luo,Etienne Lefai,John Y.-J. Shyy,Bin Gao,Michel Wierzbicki,Tony J. Verbeuren,Reuben J. Shaw,Richard A. Cohen,Mengwei Zang.AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice[J]. Cell Metabolism . 2011 (4)
  • 7John Willy Haukeland,Zbigniew Konopski,Heidi Beate Eggesb?,Hilde L?land von Volkmann,Gabriele Raschpichler,Kristian Bj?ro,Terese Haaland,Else Marit L?berg,K?re Birkeland.Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial[J]. Scandinavian Journal of Gastroenterology . 2009 (7)
  • 8Brent A. Neuschwander-Tetri,Elizabeth M. Brunt,Kent R. Wehmeier,Dana Oliver,Bruce R. Bacon.Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone[J]. Hepatology . 2003 (4)
  • 9Giulio Marchesini,Giampaolo Bianchi,Sara Tomassetti,Marco Zoli,Nazario Melchionda.Metformin in non-alcoholic steatohepatitis[J]. The Lancet . 2001 (9285)
  • 10Christopher P. Day,Oliver F.W. James.Steatohepatitis: A tale of two “hits”?[J]. Gastroenterology . 1998 (4)

共引文献20

同被引文献42

引证文献5

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部